MedTrace Logo

Trial of Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial)

NCT00228423 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 113

Last updated 2021-04-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether the combination of clopidogrel with aspirin prevents the development of blockages (atherosclerosis) in vein grafts one year after coronary artery bypass surgery (CABG) compared to aspirin alone.

Conditions

Interventions

DRUG

Clopidogrel 75 mg daily

Daily dose of 75 mg Clopidogrel

DRUG

water pill daily

Daily dose of water pill (placebo)

Sponsors & Collaborators

Principal Investigators

  • Marc Ruel, MD, MPH · Ottawa Heart Institute Research Corporation

  • Alexander Kulik, MD · Ottawa Heart Institute Research Corporation

  • Michel Le May, MD · Ottawa Heart Institute Research Corporation

  • George A Wells, PhD · Ottawa Heart Institute Research Corporation

  • Thierry G Mesana, MD, PhD · Ottawa Heart Institute Research Corporation

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2009-06-30
Completion
2009-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00228423 on ClinicalTrials.gov